Table 5.
Characteristics of studies assessing the performances of 5-ALA for the biopsy of DLGGs.
| Study | Design | Effectives | Ex Vivo Positive 5-ALA Fluorescence at Target |
|---|---|---|---|
| 5-ALA-GUIDED BIOPSIES | |||
| Von Campe, 2012 [88] | Prospective, monocentric Frameless biopsies (WHO 2007) |
14 tumors, including 2 (14.3%) DLGGs |
In 0/2 (0%) DLGGs. |
| Widhalm, 2012 [86] | Prospective, monocentric Frameless biopsies (WHO 2007) |
50 tumors, including 6 (12%) DLGGs |
In 0/19 (0%) samples from DLGGs. |
| Marbacher, 2014 [54] | Retrospective, monocentric Frameless biopsies (WHO 2007) |
82 tumors, including 12 (14.6%) DLGGs |
In 3/12 (25%) DLGGs. |
| Shofty, 2019 [89] |
Retrospective, monocentric Frameless biopsies (WHO 2007) |
34 tumors, including 3 (8.8%) DLGGs |
In 2/3 (66%) DLGGs. |
| Millesi, 2020 [90] |
Prospective, monocentric Frameless biopsies (WHO 2007 & 2016) |
79 tumors, including 6 (7.6%) DLGGs |
In 2/6 (33.3%) DLGGs (vague). |
| Malinova, 2020 [91] | Retrospective, monocentric Frame-based biopsies (WHO 2016) |
39 tumors, including 3 (7.7%) DLGGs |
In 0/3 (0%) DLGGs. |
| TOTAL | 32 DLGGs |
Positive 5-ALA fluorescence
21.9% (7/32) DLGGs |
|
| FS-GUIDED BIOPSIES | |||
| Thien, 2018 [92] |
Prospective, monocentric Frameless biopsies Dose: 5 mg/kg (WHO 2016) |
18 tumors with CE, including 3 (16.7%) DLGGs |
In 3/3 (100%) samples from DLGGs. |
| Nevzati, 2020 [52] | Prospective, monocentric Frameless biopsies Dose: 3 mg/kg (WHO 2016) |
17 tumors, including 1 (5.9%) DLGG |
In all (100%) DLGGs. |
| Xu, 2022 [87] |
Retrospective, monocentric Frameless and frame-based biopsies Dose: 5 mg/kg (WHO 2016) |
44 tumors, including 3 (6.8%) DLGGs (one astrocytoma, 2 oligodendrogliomas) |
0% of samples from grade 2 astrocytoma 36% of samples from grade 2 oligodendrogliomas, but 9% of samples were not glioma-infiltrated |
| TOTAL * | 7 DLGGs |
Positive FS fluorescence
57.1% (4/7) DLGGs |
|
* Excluding cases from [87], as the number of fluorescent samples was indicated but not that of fluorescent tumors.